<DOC>
	<DOCNO>NCT00109850</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also stop growth esophageal cancer block blood flow tumor block enzyme need cell growth . Drugs use chemotherapy , cisplatin irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving cetuximab together combination chemotherapy radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab together combination chemotherapy radiation therapy work treat patient locally advanced esophageal cancer remove surgery .</brief_summary>
	<brief_title>S0414 Cetuximab , Combo Chemo , RT Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year overall survival patient previously untreated , clinically unresectable , locally advance squamous cell carcinoma adenocarcinoma esophagus treat cetuximab , cisplatin , irinotecan , thoracic radiotherapy . Secondary - Determine toxicity profile regimen patient . - Determine probability objective response ( confirm unconfirmed , complete partial ) patient measurable disease treat regimen . - Determine time progression patient measurable disease treat regimen . - Correlate , preliminarily , gene expression ( RNA ) level germline polymorphisms gene involve DNA repair ( e.g. , ECRCC-1 XRCC-1 ) , drug metabolism ( e.g. , UGT1A1 ) , epidermal growth factor receptor ( EGFR ) pathway ( e.g. , EGFR , interleukin-8 , vascular endothelial growth factor ) response , time progression , overall survival , toxicity patient treated regimen . ( This complete study close due poor accrual . ) OUTLINE : This multicenter study . Patients receive cetuximab intravenous ( IV ) 1-2 hour day 1 , 8 , 15 . Patients also receive cisplatin IV irinotecan IV 30 minute day 1 8 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Beginning day 1 course 3 , patient undergo thoracic radiotherapy daily 5 day week 5-6 week ( total 28 treatment ) . After completion study treatment , patient follow 4 week every 3-6 month 5 year study entry . PROJECTED ACCRUAL : A total 75-100 patient ( 75 adenocarcinoma 25 squamous cell carcinoma ) accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary squamous cell carcinoma adenocarcinoma thoracic esophagus ( ≥ 20 cm incisors* ) gastroesophageal junction ( confine ≤ 2 cm gastric cardia ) Disease confine esophagus periesophageal soft tissue T4 , M0 disease Surgically unresectable disease esophageal endoscopic ultrasonography OR medically unresectable disease NOTE : *Patients primary disease &lt; 26 cm incisor must undergo bronchoscopy AND negative cytology within past 4 week Measurable nonmeasurable disease xray , CT scan and/or MRI , physical examination within past 4 week ( measurable disease ) within past 6 week ( nonmeasurable disease ) Tumor specimens available No recurrent disease PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ( ANC ) ≥ 1,500/mm^3 White Blood Cell ( WBC ) count ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL Hepatic Albumin normal Bilirubin normal Alkaline phosphatase normal Serum glutamic oxaloacetic transaminase ( SGOT ) Serum glutamic pyruvic transaminase ( SGPT ) ≤ 2.5 time upper limit normal Renal Creatinine clearance &gt; 50 mL/min Other Not pregnant nursing Fertile patient must use effective contraception No prior severe reaction monoclonal antibodies No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy esophageal cancer Endocrine therapy Not specify Radiotherapy No prior radiotherapy esophageal cancer No concurrent intensity modulate radiotherapy No concurrent cobalt60 Surgery No prior surgical resection attempt surgical resection esophageal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>